Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04640610

Angiotensin-converting Enzyme 2 (ACE2) Expression in Tonsils and Adenoids

Study of the Expression of Angiotensin-converting Enzyme 2 (ACE2), a Cell Membrane Receptor for SARS-CoV-2 and the TMPRSS2 Serine Protease in Tonsils and Adenoids of Children and Adults

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The objective of the research is to study the expression of the ACE 2 receptor and the TMPRSS2 serine protease in the tonsils and adenoids of children and adults.

Detailed description

The entry point for SARS-CoV-2 into the body is the nasal and pharyngeal mucosa. Angiotensin-converting enzyme 2 (ACE 2) was quickly identified as the functional receptor for SARS-CoV-2. Furthermore, the TMPRSS2 serine protease is required for the anchoring of the S protein in cell lines. In addition, the most commonly used screening test is a test for viral RNA by RT-PCR on a nasopharyngeal sample because the viral load is high. The tonsils and adenoids could be a target organ of the virus. In order to study this hypothesis, the expression of ACE 2 and the serine protease TMPRSS2 will be sought in these tissues. In addition, children, generally at high risk of severe viral respiratory infections (RSV, influenza), have milder symptoms than older patients with SARS-CoV-2 infection. The reason for this difference remains elusive. But one of the hypotheses formulated is that the level of expression of ACE 2 and / or TMPRSS2 may differ between adults and children, the viral load seeming to be correlated with the severity of the attack. In order to study this hypothesis, we will therefore compare the level of expression of ACE 2 in the tonsil tissue of children and adults.

Conditions

Interventions

TypeNameDescription
OTHERStorage of operating wasteStorage of operating waste of adenoidectomy / tonsillectomy

Timeline

Start date
2021-06-30
Primary completion
2021-06-30
Completion
2021-06-30
First posted
2020-11-23
Last updated
2026-03-12

Locations

9 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04640610. Inclusion in this directory is not an endorsement.